XML 21 R26.htm IDEA: XBRL DOCUMENT v3.20.1
Segment Reporting (Tables)
3 Months Ended
Mar. 31, 2020
Segment Reporting [Abstract]  
Summary of Financial Information with Respect to Reportable Segments

All segment revenue is earned in the United States and there are no intersegment revenues. Additionally, the Company reports assets on a consolidated basis and does not allocate assets to its reportable segments for purposes of assessing segment performance or allocating resources. Presented below is financial information with respect to the Company’s reportable segments for the periods presented:

 

 

 

Three Months Ended March 31,

 

 

 

2020

 

 

2019

 

Segment revenues:

 

 

 

 

 

 

 

 

Software

 

$

23,812

 

 

$

18,605

 

Drug discovery

 

 

2,362

 

 

 

2,136

 

Total segment revenues

 

$

26,174

 

 

$

20,741

 

Segment gross profit:

 

 

 

 

 

 

 

 

Software

 

$

19,811

 

 

$

15,472

 

Drug discovery

 

 

(4,186

)

 

 

(2,468

)

Total segment gross profit

 

 

15,625

 

 

 

13,004

 

Unallocated:

 

 

 

 

 

 

 

 

Research and development expense

 

 

(13,700

)

 

 

(8,438

)

Sales and marketing expense

 

 

(4,789

)

 

 

(5,093

)

General and administrative expense

 

 

(8,936

)

 

 

(5,086

)

Change in fair value

 

 

(3,079

)

 

 

(627

)

Interest income

 

 

699

 

 

 

438

 

Income tax expense

 

 

(91

)

 

 

(46

)

Consolidated net loss

 

$

(14,271

)

 

$

(5,848

)

Schedule of Revenues by Geographic Area

The following table sets forth revenues by geographic area for the three months ended March 31, 2020 and 2019:

 

 

 

Three Months Ended March 31,

 

 

 

2020

 

 

2019

 

United States

 

$

13,486

 

 

$

9,872

 

Europe

 

 

8,281

 

 

 

6,440

 

Japan

 

 

1,970

 

 

 

2,664

 

Rest of World

 

 

2,437

 

 

 

1,765

 

 

 

$

26,174

 

 

$

20,741